Literature DB >> 15797997

Apoptosis-based therapies for hematologic malignancies.

John C Reed1, Maurizio Pellecchia.   

Abstract

Apoptosis is an intrinsic cell death program that plays critical roles in tissue homeostasis, especially in organs where high rates of daily cell production are offset by rapid cell turnover. The hematopoietic system provides numerous examples attesting to the importance of cell death mechanisms for achieving homeostatic control. Much has been learned about the mechanisms of apoptosis of lymphoid and hematopoietic cells since the seminal observation in 1980 that glucocorticoids induce DNA fragmentation and apoptosis of thymocytes and the demonstration in 1990 that depriving colony-stimulating factors from factor-dependent hematopoietic cells causes programmed cell death. From an understanding of the core components of the apoptosis machinery at the molecular and structural levels, many potential new therapies for leukemia and lymphoma are emerging. In this review, we introduce some of the drug discovery targets thus far identified within the core apoptotic machinery and describe some of the progress to date toward translating our growing knowledge about these targets into new therapies for cancer and leukemia.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15797997     DOI: 10.1182/blood-2004-07-2761

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  118 in total

1.  Emerging Therapeutic Targets in Diffuse Large B-Cell Lymphoma.

Authors:  Murali Janakiram; Venu K Thirukonda; Matthew Sullivan; Adam M Petrich
Journal:  Curr Treat Options Oncol       Date:  2012-02-02

2.  One cell's poison is another cell's cure.

Authors:  Raymond A Swanson
Journal:  Nat Neurosci       Date:  2012-03-27       Impact factor: 24.884

3.  Tounongsan extract induces apoptosis in cultured Raji cells.

Authors:  Liang-Hua Fang; Rui-Ping Wang; Shou-You Hu; Li Zhang; Shen-Lin Liu
Journal:  Chin J Integr Med       Date:  2012-07-07       Impact factor: 1.978

4.  Ethyl acetate extract and its major constituent, isorhamnetin 3-O-rutinoside, from Nitraria retusa leaves, promote apoptosis of human myelogenous erythroleukaemia cells.

Authors:  J Boubaker; W Bhouri; M Ben Sghaier; K Ghedira; M G Dijoux Franca; L Chekir-Ghedira
Journal:  Cell Prolif       Date:  2011-10       Impact factor: 6.831

Review 5.  Chemistry and biology of the caged Garcinia xanthones.

Authors:  Oraphin Chantarasriwong; Ayse Batova; Warinthorn Chavasiri; Emmanuel A Theodorakis
Journal:  Chemistry       Date:  2010-09-03       Impact factor: 5.236

Review 6.  The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitors.

Authors:  James W Hodge; Andressa Ardiani; Benedetto Farsaci; Anna R Kwilas; Sofia R Gameiro
Journal:  Semin Oncol       Date:  2012-06       Impact factor: 4.929

Review 7.  Chemotherapeutic approaches for targeting cell death pathways.

Authors:  M Stacey Ricci; Wei-Xing Zong
Journal:  Oncologist       Date:  2006-04

8.  Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia.

Authors:  Rosa Lapalombella; Qingxiang Sun; Katie Williams; Larissa Tangeman; Shruti Jha; Yiming Zhong; Virginia Goettl; Emilia Mahoney; Caroline Berglund; Sneha Gupta; Alicia Farmer; Rajeswaran Mani; Amy J Johnson; David Lucas; Xiaokui Mo; Dirk Daelemans; Vincent Sandanayaka; Sharon Shechter; Dilara McCauley; Sharon Shacham; Michael Kauffman; Yuh Min Chook; John C Byrd
Journal:  Blood       Date:  2012-10-03       Impact factor: 22.113

9.  Sodium arsenite accelerates TRAIL-mediated apoptosis in melanoma cells through upregulation of TRAIL-R1/R2 surface levels and downregulation of cFLIP expression.

Authors:  Vladimir N Ivanov; Tom K Hei
Journal:  Exp Cell Res       Date:  2006-09-28       Impact factor: 3.905

10.  Gambogic acid is an antagonist of antiapoptotic Bcl-2 family proteins.

Authors:  Dayong Zhai; Chaofang Jin; Chung-Wai Shiau; Shinichi Kitada; Arnold C Satterthwait; John C Reed
Journal:  Mol Cancer Ther       Date:  2008-06       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.